Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression profile of Ras, MEK and ERK inhibited 16HBE bronchial epithelial cells

ABSTRACT: To identify Ras, MEK and ERK target genes which regulate tight junction formation in 16HBE bronchial epithelial cells

ORGANISM(S): Homo sapiens

PROVIDER: GSE63229 | GEO | 2018/12/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Paired MEK inhibited and control

2009-02-11 | GSE10087 | GEO

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy.

Project description: Not available

| S-EPMC7017232 | biostudies-literature

Drosera rotundifolia induces gene expression changes in human bronchial epithelial cells 16HBE

Project description:16HBE cells were incubated for 3 or 6h with a homeopathic preparation of Drosera r. or the solvent control and the transcriptome was analyzed by RNA sequencing. The expression changes of the main statistically significant genes were validated through follow-up experiments using RT-qPCR. Compared with the control solution, Drosera r. changed the expression of dozens of genes already after 3h and this effect was amplified after 6 hours of treatment. The main target genes were some ligands of epithelial growth factor receptor (EREG, AREG, EPGN), genes involved in xenobiotic detoxification (CYP1B1, TIPARP) and chemokines. The network of the main biological functions included epithelial cell proliferation, regulation of angiogenesis, cell chemotaxis, and wound healing. Drosera r. acts on a complex and faceted set of genes, potentially involved in different layers of the bronchial mucosa. The global effect of the plant in 16HBE epithelial cells is a mild stress response that primes the epithelial reparative process and recruits the innate cell defense.

2021-02-02 | GSE144215 | GEO

TNF-a-induced MEK/ERK-dependent regulation of Cartilage Matrix Genes

Project description:TNF-a is increased in the synovial fluid of patients with rheumatoid arthritis and osteoarthritis. TNF-a activates MEK/ERK in chondrocytes; however the overall functional relevance of MEK/ERK to TNF-a-regulated gene expression in chondrocytes is unknown. Chondrocytes were treated with TNF-a with or without the MEK1/2 inhibitor U0126 for 24 h. Microarray analysis was used to identify genes regulated by TNF-a in a MEK1/2-dependent fashion. Keywords: compound, signalling response

2009-01-14 | GSE14402 | GEO

Transcription profiling of mouse chondrocytes treated with MEK/ERK pathway inhibitors

Project description:Objectives: To identify similarities and differences in gene expression data in the MEK/ERK and PI3K pathways and to determine how histone modification affects these same pathways. Goal: To identify and functionally characterize novel targets of these signaling pathways in the context of chondrocyte differentiation. Experiment Overall Design: Cartilage derived from the hind limbs of CD1 mice staged at 15.5 days of embryonic development were dissected and plated in primary chondrocyte monolayer cultures. Cells were treated with MEK/ERK pathway inhibitors (SB202190 and UO126), a PI3K inhibitor (LY294002), a histone deacetylase inhibitor (Trichostatin A) and the vehicle control (DMSO) for 24 hours. Total RNA was isolated from these samples and hybridized to Affymetrix MOE 430 2.0 chips at the London Regional Genomics facility. Experiment Overall Design: A total of 15 genechips were analyzed between 4 treatments and the vehicle (DMSO) control. Three biological replicates per treatment were executed. Experiment Overall Design: Experiment Overall Design:

2009-05-11 | E-GEOD-15069 | biostudies-arrayexpress

Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Anti-Tumor T-cell Immunity [TCR-seq]

Project description:Disruption of the MAPK pathway in cancer by kinase inhibition often fails due to pathway reactivation, causing clinical relapse. Among MAPK inhibitors, type I RAF inhibitors are only active against specific BRAF mutants; MEK inhibitor monotherapy is associated with limited clinical benefits but may serve as a foundation for combinatorial therapy. Here, we show that type II RAF plus allosteric MEK inhibitors durably blunt the development of acquired MEK inhibitor resistance among cancers with KRAS, NRAS, NF1, BRAFnon-V600 and BRAFV600 mutations, when compared to a combination of type II RAF plus ERK inhibitors. Type II RAF and MEK (versus ERK) inhibitors also display superior capacity to sequester MEK in RAF complexes and uncouple MEK and ERK interaction in acquired resistant tumor subpopulations. Systemically and intratumorally, type II RAF plus MEK inhibitors expand memory and activated/exhausted CD8+ T-cells. Whereas trametinib alone temporally reduces dominant intra-tumoral T-cell clones, type II RAF inhibitor co-treatment reverses this effect and promotes T-cell clonotypic expansion and convergence. Importantly, durably control of tumors by this combination requires CD8+ T-cells. Thus, the prolonged anti-tumor efficacy of type II RAF plus MEK inhibitors reveals exquisite MAPK addiction in common lethal cancer histologies, and the mechanisms include unexpected allosteric perturbation of the MAPK pathway and engagement of anti-tumor CD8+ T-cell immunity.

2021-06-06 | GSE158608 | GEO

Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Anti-Tumor T-cell Immunity [RNA-seq]

2021-06-06 | GSE158607 | GEO

Transcription profiling of human cell lines in culture (n=12) and murine xenografts (n=2) were treated with the MEK inhibitor PD0325901 or vehicle alone as controlPaired MEK inhibited and control

Project description:This study used microarray expression analysis to identify global changes in transcript alteration in response to MEK inhibition. Genes under ERK control were identified in a panel of V600E BRAF and RTK-activated tumor cells and xenografts, using short-term inhibition of ERK activity using the MEK inhibitor PD0325901 (Pfizer). Experiment Overall Design: Cell lines growing in culture (n=12) and murine xenografts (n=2) were treated with the MEK inhibitor PD0325901 or vehicle alone as control. Paired analysis of MEK inhibited to control samples was performed for two groups of tumor cells, V600E BRAF and RTK.

2009-02-21 | E-GEOD-10087 | biostudies-arrayexpress

Polymorphisms in RAS/RAF/MEK/ERK Pathway Are Associated with Gastric Cancer.

Project description: Not available

| S-EPMC6356706 | biostudies-literature

Reusability and composability in process description maps: RAS-RAF-MEK-ERK signalling.

Project description: Not available

| S-EPMC8425390 | biostudies-literature